

**ASX RELEASE** 

6 May 2020

Not for release to US newswire services or distribution in the United States

# KAZIA SHARE PURCHASE PLAN RAISES A\$1.8 MILLION

Sydney, 6 May 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the Share Purchase Plan (SPP), as described in the SPP booklet dated 17 April 2020, has now closed.

The SPP offered eligible shareholders in Australia and New Zealand the opportunity to apply for up to A\$30,000 worth of new fully paid ordinary shares in Kazia, without incurring brokerage or other transaction costs. Shares under the SPP were offered at a price of A\$0.40 per share, which was equal to the price under the institutional placement announced by Kazia on Wednesday, 8 April 2020.

The SPP successfully raised approximately A\$1.8 million. The proceeds from the SPP and the Placement will be used to progress the paxalisib clinical trial program and to complete analysis of the ongoing Phase I study of Cantrixil, to continue to provide contributory funding towards four other trials, and as working capital for the Company.

Kazia Chairman, Iain Ross, commented, "following our successful institutional placement in early April, the Board considered it imperative that existing shareholders have the opportunity to augment their holdings in the company at the same price as the institutional investors. We are delighted to have received a very high level of engagement with this SPP. As on previous occasions, the proceeds will be applied directly to progressing and enriching the company's R&D programs. We expect paxalisib to transition to a pivotal study in the second half of this year, so it is a particularly critical time for the company. We are, as always, grateful for the strong and enthusiastic support of our shareholders and look forward to sharing further progress as the year advances."

Approximately 4.5 million new shares will be issued under the SPP. It is expected that new shares under the SPP will be issued by Kazia and allotted to successful applicants on Monday, 11 May 2020. Normal trading of SPP shares is expected to commence on Tuesday, 12 May 2020, with holding statements to be dispatched around Thursday, 14 May 2020.

[ENDS]

#### **Board of Directors**

# **About Kazia Therapeutics Limited**

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxalisib was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Interim data was presented at the ESMO Congress in September 2019, and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

### **Summary Information**

The following disclaimer applies to this announcement and any information contained in it (the **Information**). The Information in this announcement is of general background and does not purport to be complete. It should be read in conjunction with Kazia's other periodic and continuous disclosure announcements lodged with ASX Limited, which are available at www.asx.com.au. You are advised to read this disclaimer carefully before reading or making any other use of this announcement or any Information contained in this announcement. In accepting this announcement, you agree to be bound by the following terms and conditions including any modifications to them.

### **Forward Looking Statements**

This announcement may include forward-looking statements. These forward-looking statements are based on Kazia's expectations and beliefs concerning future events. Forward looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Kazia, which could cause actual results to differ materially from such statements. Kazia makes no undertaking to subsequently update or revise the forward-looking statements made in this announcement, to reflect the circumstances or events after the date of this announcement.

## Not for release in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States

or any other jurisdiction in which such an offer would be illegal. The securities referred to in this announcement have not been, nor will be, registered under the US Securities Act of 1933 (Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, such securities may not be offered or sold, directly or indirectly, in the United States or to any US person (as defined in Rule 902 under the Securities Act) or to any person acting for the account or benefit of a US person, except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States.